Signaling Mechanisms Responsible for Lysophosphatidic Acid-induced Urokinase Plasminogen Activator Expression in Ovarian Cancer Cells*

Lysophosphatidic acid (LPA) enhances urokinase plasminogen activator (uPA) expression in ovarian cancer cells; however, the molecular mechanisms responsible for this event have not been investigated. In this study, we used the invasive ovarian cancer SK-OV-3 cell line to explore the signaling molecules and pathways essential for LPA-induced uPA up-regulation. With the aid of specific inhibitors and dominant negative forms of signaling molecules, we determined that the Gi-associated pathway mediates this LPA-induced event. Moreover, constitutively active H-Ras and Raf-1-activating H-Ras mutant enhance uPA expression, whereas dominant negative H-Ras and Raf-1 block LPA-induced uPA up-regulation, suggesting that the Ras-Raf pathway works downstream of Gi to mediate this LPA-induced process. Surprisingly, dominant negative MEK1 or Erk2 displays only marginal inhibitory effect on LPA-induced uPA up-regulation, suggesting that a signaling pathway distinct from Raf-MEK1/2-Erk is the prominent pathway responsible for this process. In this report, we demonstrate that LPA activates NF-κB in a Ras-Raf-dependent manner and that blocking NF-κB activation with either non-phosphorylable IκB or dominant negative IκB kinase abolished LPA-induced uPA up-regulation and uPA promoter activation. Furthermore, introducing mutations to knock out the NF-κB binding site of the uPA promoter results in over 80% reduction in LPA-induced uPA promoter activation, whereas this activity is largely intact with the promoter containing mutations in the AP1 binding sites. Thus these results suggest that the Gi-Ras-Raf-NF-κB signaling cascade is responsible for LPA-induced uPA up-regulation in ovarian cancer cells.

[1]  G. Mills,et al.  The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer. , 2003, Cancer research.

[2]  Y. Saga,et al.  Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cell line by overexpression of bikunin , 2003 .

[3]  G. Mills,et al.  Lysophospholipid Growth Factors in the Initiation, Progression, Metastases, and Management of Ovarian Cancer , 2000, Annals of the New York Academy of Sciences.

[4]  E. Lengyel,et al.  Involvement of a Mitogen-activated Protein Kinase Signaling Pathway in the Regulation of Urokinase Promoter Activity by c-Ha-ras(*) , 1995, The Journal of Biological Chemistry.

[5]  A. Hall,et al.  Rac Mediates Cytoskeletal Rearrangements and Increased Cell Motility Induced by Urokinase-Type Plasminogen Activator Receptor Binding to Vitronectin , 2001, The Journal of cell biology.

[6]  P. Dettmar,et al.  Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. , 1994, Gynecologic oncology.

[7]  W. Kolch,et al.  The Raf‐1 kinase associates with vimentin kinases and regulates the structure of vimentin filaments , 2000, The FASEB Journal.

[8]  A. Villa,et al.  Src-dependence and pertussis-toxin sensitivity of urokinase receptor-dependent chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. , 1999, Blood.

[9]  Y. Hirashima,et al.  Suppression of Urokinase Expression and Invasiveness by Urinary Trypsin Inhibitor Is Mediated through Inhibition of Protein Kinase C- and MEK/ERK/c-Jun-dependent Signaling Pathways* , 2001, The Journal of Biological Chemistry.

[10]  G. V. Vande Woude,et al.  Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network , 1996, Molecular and cellular biology.

[11]  E. Goetzl,et al.  Lysophospholipid mediators of immunity and neoplasia. , 2002, Biochimica et biophysica acta.

[12]  M Markman,et al.  Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. , 1998, JAMA.

[13]  Chen-Yong Lin,et al.  Inhibition of Tumor Invasion by Genomic Down-regulation of Matriptase through Suppression of Activation of Receptor-bound Pro-urokinase* , 2004, Journal of Biological Chemistry.

[14]  N. Harbeck,et al.  Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function , 1998, FEBS letters.

[15]  G. Johnson,et al.  Direct Interaction between Ras and the Kinase Domain of Mitogen-activated Protein Kinase Kinase Kinase (MEKK1) (*) , 1995, The Journal of Biological Chemistry.

[16]  K. Okada,et al.  Co-localization of urokinase and its receptor on established human umbilical vein endothelial cell. , 1999, Cell structure and function.

[17]  D. Collen The Plasminogen (Fibrinolytic) System , 1999, Thrombosis and Haemostasis.

[18]  Shuang Huang,et al.  Rac1-MKK3-p38-MAPKAPK2 Pathway Promotes Urokinase Plasminogen Activator mRNA Stability in Invasive Breast Cancer Cells* , 2002, The Journal of Biological Chemistry.

[19]  M. Schmitt,et al.  Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice , 1995, Clinical & Experimental Metastasis.

[20]  E. Lengyel,et al.  Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  R. Kumar,et al.  Heregulin regulation of urokinase plasminogen activator and its receptor: human breast epithelial cell invasion. , 2001, Cancer research.

[22]  Zhimin Lu,et al.  RalA requirement for v-Src- and v-Ras-induced tumorigenicity and overproduction of urokinase-type plasminogen activator: involvement of metalloproteases , 1999, Oncogene.

[23]  Michael S. Pepper,et al.  Membrane proteases in focus , 1994, Nature.

[24]  B. Giepmans,et al.  The ins and outs of lysophosphatidic acid signaling , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[25]  C. Borgfeldt,et al.  Dedifferentiation of serous ovarian cancer from cystic to solid tumors is associated with increased expression of mRNA for urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor (PAI‐1) , 2001, International journal of cancer.

[26]  S. Rabbani,et al.  Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies. , 1998, International journal of oncology.

[27]  F. Imamura,et al.  Inhibition of tumor invasion and metastasis by a novel lysophosphatidic acid (cyclic LPA) , 1999, International journal of cancer.

[28]  J. Sedivy,et al.  Raf-1 protein kinase activates the NF-kappa B transcription factor by dissociating the cytoplasmic NF-kappa B-I kappa B complex. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[29]  G. Mills,et al.  Mechanisms for Lysophosphatidic Acid-induced Cytokine Production in Ovarian Cancer Cells* , 2004, Journal of Biological Chemistry.

[30]  R. Gertz,et al.  The significance of urokinase‐type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer , 1995, Cancer.

[31]  G. Mills,et al.  Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  Jing Chen,et al.  Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK–ERK independent mechanism , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[33]  G. Nemerow,et al.  Urokinase Plasminogen Activator/Urokinase-specific Surface Receptor Expression and Matrix Invasion by Breast Cancer Cells Requires Constitutive p38α Mitogen-activated Protein Kinase Activity* , 2000, The Journal of Biological Chemistry.

[34]  Shuang Huang,et al.  Chemoattractant-stimulated NF-κB Activation Is Dependent on the Low Molecular Weight GTPase RhoA* , 2001, The Journal of Biological Chemistry.

[35]  S. Miyamoto,et al.  Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer. , 2003, Cancer letters.

[36]  C. Gondi,et al.  Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis , 2003, Oncogene.

[37]  J. Chun,et al.  Lysophosphatidic acid as a novel cell survival/apoptotic factor. , 2002, Biochimica et biophysica acta.

[38]  G. Mills,et al.  Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. , 2001, Journal of the National Cancer Institute.

[39]  O. Kranenburg,et al.  Ras-MAP kinase signaling by lysophosphatidic acid and other G protein-coupled receptor agonists , 2001, Oncogene.

[40]  G. Bren,et al.  The Ras-Raf pathway is activated in human immunodeficiency virus-infected monocytes and particpates in the activation of NF-kappa B , 1996, Journal of virology.

[41]  G. Nemerow,et al.  Integrins α v β 3 and α v β 5 promote adenovirus internalization but not virus attachment , 1993, Cell.

[42]  A. Morris,et al.  Role of phospholipase D in agonist-stimulated lysophosphatidic acid synthesis by ovarian cancer cells Published, JLR Papers in Press, July 1, 2003. DOI 10.1194/jlr.M300188-JLR200 , 2003, Journal of Lipid Research.

[43]  Yan Xu,et al.  Lysophospholipids increase interleukin-8 expression in ovarian cancer cells. , 2001, Gynecologic oncology.

[44]  John Calvin Reed,et al.  Bcl-2 Targets the Protein Kinase Raf-1 to Mitochondria , 1996, Cell.

[45]  B. Giepmans,et al.  Lysophosphatidic acid: mitogen and motility factor. , 2003, Biochemical Society transactions.

[46]  A. Krüger,et al.  High‐affinity urokinase‐derived cyclic peptides inhibiting urokinase/urokinase receptor‐interaction: effects on tumor growth and spread , 2002, FEBS letters.

[47]  Gordon B Mills,et al.  Lysophosphatidic acid is a bioactive mediator in ovarian cancer. , 2002, Biochimica et biophysica acta.

[48]  M. Schmitt,et al.  Rel transcription factors contribute to elevated urokinase expression in human ovarian carcinoma cells. , 1999, European journal of biochemistry.

[49]  L. Matrisian,et al.  Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis , 1995, Cancer and Metastasis Reviews.

[50]  J. Oh,et al.  Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase. , 2001, Cancer research.

[51]  G. Mills,et al.  Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[52]  L. Guerrini,et al.  NF‐κB‐mediated regulation of urokinase gene expression by PMA and TNF‐α in human A549 cells , 1996 .

[53]  R. Lefkowitz,et al.  New mechanisms in heptahelical receptor signaling to mitogen activated protein kinase cascades , 2001, Oncogene.

[54]  L. Liotta,et al.  General mechanisms of metastasis , 1997, Cancer.

[55]  S. Demo,et al.  ralGDS family members interact with the effector loop of ras p21 , 1994, Molecular and cellular biology.

[56]  A. Kusch,et al.  Urokinase Stimulates Human Vascular Smooth Muscle Cell Migration via a Phosphatidylinositol 3-Kinase-Tyk2 Interaction* , 2000, The Journal of Biological Chemistry.

[57]  J. Weiner,et al.  Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[58]  J. Chun,et al.  Characterization of lpa2 (Edg4) and lpa1/lpa2 (Edg2/Edg4) Lysophosphatidic Acid Receptor Knockout Mice: Signaling Deficits without Obvious Phenotypic Abnormality Attributable to lpa2 , 2002, Molecular and Cellular Biology.

[59]  D. Morrison,et al.  Characterization of Raf-1 Activation in Mitosis* , 1999, The Journal of Biological Chemistry.

[60]  G. Rice,et al.  Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression. , 2004, Gynecologic oncology.

[61]  E. Goetzl,et al.  Lysophosphatidic Acid Receptor-Selective Effects on Jurkat T Cell Migration Through a Matrigel Model Basement Membrane1 , 2001, The Journal of Immunology.

[62]  Shuang Huang,et al.  Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 Pathway , 2004, Cancer Research.

[63]  G. Nemerow,et al.  Apoptosis signaling pathway in T cells is composed of ICE/Ced-3 family proteases and MAP kinase kinase 6b. , 1997, Immunity.

[64]  E. Rozengurt,et al.  Cooperation of Gq, Gi, and G12/13 in Protein Kinase D Activation and Phosphorylation Induced by Lysophosphatidic Acid* , 2003, The Journal of Biological Chemistry.

[65]  J. Wood,et al.  Specific keynote: molecular determinants of angiogenesis in ovarian cancer. , 2003, Gynecologic oncology.

[66]  J. Chun,et al.  Lysophospholipid G Protein-coupled Receptors* , 2004, Journal of Biological Chemistry.

[67]  D. Fishman,et al.  Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. , 2001, Cancer research.

[68]  F. Blasi Proteolysis, Cell Adhesion, Chemotaxis, and Invasiveness Are Regulated by the u-PA-u-PAR-PAI-1 System , 1999, Thrombosis and Haemostasis.

[69]  L. Liotta,et al.  Molecular aspects of tumor cell invasion and metastasis , 1993, Cancer.

[70]  M. Wigler,et al.  Stimulation of Membrane Ruffling and MAP Kinase Activation by Distinct Effectors of RAS , 1996, Science.

[71]  F. Bertrand,et al.  Insulin Activates Nuclear Factor κB in Mammalian Cells through a Raf-1-mediated Pathway (*) , 1995, The Journal of Biological Chemistry.

[72]  S. Nakano,et al.  Simultaneous up-regulation of urokinase-type plasminogen activator (uPA) and uPA receptor by hepatocyte growth factor/scatter factor in human glioma cells , 2004, Clinical & Experimental Metastasis.

[73]  G. Mills,et al.  Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[74]  R. Kimmig,et al.  Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[75]  M. Wigler,et al.  Multiple ras functions can contribute to mammalian cell transformation , 1995, Cell.

[76]  T. Nakamura,et al.  Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing Met. , 1998, The American journal of pathology.